Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs

被引:24
作者
Hayashi, K
Fukuda, Y
Nakano, I
Katano, Y
Yokozaki, S
Toyoda, H
Takamatsu, J
Hayakawa, T
机构
[1] Nagoya Univ, Sch Med, Dept Internal Med 2, Showa Ku, Aichi 4668550, Japan
[2] Fujita Hlth Univ, Sch Med, Dept Internal Med, Toyoake, Aichi 47011, Japan
[3] Nagoya Univ, Sch Med, Dept Transfus Med, Aichi 4668550, Japan
关键词
CD4; counts; chronic hepatitis C; haemophiliacs; hepatitis C virus; human immunodeficiency virus; interferon therapy;
D O I
10.1046/j.1365-2516.2000.00444.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We performed a pilot study to evaluate the factors associated with response to interferon (IFN) therapy for chronic hepatitis C (CHC) with human immunodeficiency virus (HIV) coinfected haemophiliacs. Seven haemophiliacs, coinfected with HIV and hepatitis C virus (HCV), received 9 megaunits (MU) of natural IFN-alpha daily during the first 2 weeks and then three times a week for 22 weeks, all injected subcutaneously. Six patients were receiving zidovudine (AZT) 600 mg day(-1) and didanosine (ddI) 200 mg day(-1) during IFN therapy. This treatment was safe and well tolerated. Four patients had no detectable serum HCV-RNA at the end of therapy, but long-term, none of the seven patients achieved a sustained response, i.e. undetectable serum HCV-RNA with persistently normal serum alanine aminotransferase (ALT) 6 months after therapy. IFN did not affect CD4-positive cell counts. Most of our patients had high HCV-RNA loads and/or low CD4 counts, both unfavourable markers for IFN therapy. In conclusion, IFN therapy did not eradicate HCV from haemophiliacs coinfected with HIV.
引用
收藏
页码:677 / 681
页数:5
相关论文
共 25 条
[1]  
Ahmed MM, 1999, HAEMOPHILIA, V5, P49
[2]   RECOMBINANT INTERFERON-ALPHA FOR CHRONIC HEPATITIS-C IN PATIENTS POSITIVE FOR ANTIBODY TO HUMAN-IMMUNODEFICIENCY-VIRUS [J].
BOYER, N ;
MARCELLIN, P ;
DEGOTT, C ;
DEGOS, F ;
SAIMOT, AG ;
ERLINGER, S ;
BENHAMOU, JP .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (04) :723-726
[3]  
BRETTLER DB, 1990, BLOOD, V76, P254
[4]   TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL [J].
DAVIS, GL ;
BALART, LA ;
SCHIFF, ER ;
LINDSAY, K ;
BODENHEIMER, HC ;
PERRILLO, RP ;
CAREY, W ;
JACOBSON, IM ;
PAYNE, J ;
DIENSTAG, JL ;
VANTHIEL, DH ;
TAMBURRO, C ;
LEFKOWITCH, J ;
ALBRECHT, J ;
MESCHIEVITZ, C ;
ORTEGO, TJ ;
GIBAS, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1501-1506
[5]  
DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629
[6]   RECOMBINANT INTERFERON-ALFA THERAPY FOR CHRONIC HEPATITIS-C - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DIBISCEGLIE, AM ;
MARTIN, P ;
KASSIANIDES, C ;
LISKERMELMAN, M ;
MURRAY, L ;
WAGGONER, J ;
GOODMAN, Z ;
BANKS, SM ;
HOOFNAGLE, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1506-1510
[7]  
EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P602
[8]  
EYSTER ME, 1994, BLOOD, V84, P1020
[9]   Interferon treatment for chronic hepatitis C infection in hemophiliacs - Influence of virus load, genotype, and liver pathology on response [J].
Hanley, JP ;
Jarvis, LM ;
Andrews, J ;
Dennis, R ;
Hayes, PC ;
Piris, J ;
Lee, R ;
Simmonds, P ;
Ludlam, CA .
BLOOD, 1996, 87 (05) :1704-1709
[10]   SIGNIFICANCE OF SERUM HEPATITIS-C VIRUS-RNA LEVELS IN CHRONIC HEPATITIS-C [J].
LAU, JYN ;
DAVIS, GL ;
KNIFFEN, J ;
QIAN, KP ;
URDEA, MS ;
CHAN, CS ;
MIZOKAMI, M ;
NEUWALD, PD ;
WILBER, JC .
LANCET, 1993, 341 (8859) :1501-1504